CytomX Therapeutics (NASDAQ:CTMX) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Thursday.

A number of other equities analysts also recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of CytomX Therapeutics in a research note on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price target on the stock. Bank of America upped their price target on shares of CytomX Therapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Zacks Investment Research downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Nomura upped their price target on shares of CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research note on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $31.88.

CytomX Therapeutics (CTMX) traded up $0.44 during midday trading on Thursday, hitting $20.56. 306,168 shares of the stock were exchanged, compared to its average volume of 371,081. CytomX Therapeutics has a 1-year low of $10.40 and a 1-year high of $24.67.

In other CytomX Therapeutics news, Director Frederick W. Gluck sold 5,000 shares of the stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $17.30, for a total transaction of $86,500.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Robert I. Tepper sold 24,777 shares of the stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $24.34, for a total transaction of $603,072.18. The disclosure for this sale can be found here. Insiders have sold 173,009 shares of company stock worth $3,835,417 over the last three months. Company insiders own 4.70% of the company’s stock.

A number of institutional investors have recently bought and sold shares of CTMX. New York State Common Retirement Fund grew its position in shares of CytomX Therapeutics by 48.8% in the second quarter. New York State Common Retirement Fund now owns 31,100 shares of the biotechnology company’s stock valued at $482,000 after purchasing an additional 10,199 shares during the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of CytomX Therapeutics in the first quarter valued at about $190,000. TIAA CREF Investment Management LLC grew its position in shares of CytomX Therapeutics by 183.7% in the second quarter. TIAA CREF Investment Management LLC now owns 169,552 shares of the biotechnology company’s stock valued at $2,628,000 after purchasing an additional 109,791 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of CytomX Therapeutics in the third quarter valued at about $474,000. Finally, California State Teachers Retirement System grew its position in shares of CytomX Therapeutics by 27.8% in the second quarter. California State Teachers Retirement System now owns 51,430 shares of the biotechnology company’s stock valued at $797,000 after purchasing an additional 11,200 shares during the last quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/09/bidaskclub-lowers-cytomx-therapeutics-ctmx-to-hold.html.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.